Steroid refractory CD4+ T cells in patients with sight-threatening uveitis

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 9, 2009, Pages 4273-4278

  Lee, Richard W J ^a,b   Schewitz, Lauren P ^b   Nicholson, Lindsay B ^b   Dayan, Colin M ^b   Dick, Andrew D ^a,b  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB; DEXAMETHASONE; INTERLEUKIN 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STEROID; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UVEITIS; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; DEXAMETHASONE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; UVEITIS; YOUNG ADULT;

EID: 70349240428     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3152     Document Type: Article

References (29)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491-500.
2. Williams GJ, Brannan S, Forrester JV, et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol. 2007;91: 33-36.
3. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
4. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.
5. de Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990;74: 344-349.
6. Howe LJ, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye. 1994;8:443-447.
7. Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease: mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111-122.
8. Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest. 1994;93:33-39.
9. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516.
10. +CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids. J Immunol. 2007;179:7941-7948.
11. Goleva E, Kisich KO, Leung DY. A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J Immunol. 2002;169:5934-5940.
12. Spahn JD, Landwehr LP, Nimmagadda S, Surs W, Leung DY, Szefler SJ. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol. 1996;98:1073-1079.
13. Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroidresistant asthma. J Exp Med. 1995;181:33-40.
14. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol. 1993;151:3460-3466.
15. Walker KB, Potter JM, House AK. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol. 1987;68:162-167.
16. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147-154.
17. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645-648.
18. Nielsen M, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94:6764-6769.
19. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Malden, MA: Blackwell Science; 2003:501.
20. Norman M, Hearing SD. Glucocorticoid resistance: what is known? Curr Opin Pharmacol. 2002;2:723-729.
21. Sliwinska-Stanczyk P, Pazdur J, Ziolkowska M, Jaworski J, Kaminska-Tchorzewska E, Lacki JK. The effect of methylprednisolone on proliferation of PBMCs obtained from steroid-sensitive and steroidresistant rheumatoid arthritis patients. Scand J Rheumatol. 2007; 36:167-171.
22. Schewitz LP, Lee RW, Dayan CM, Dick AD. Glucocorticoids and the emerging importance of T cell subsets in steroid refractory diseases. Immunopharmacol Immunotoxicol. 2008;1-22.
23. Gillis S, Crabtree GR, Smith KA. Glucocorticoid-induced inhibition of T cell growth factor production, I: the effect on mitogeninduced lymphocyte proliferation. J Immunol. 1979;123:1624-1631.
24. Gregory CR. Immunosuppressive approaches to the prevention of graft vascular disease. Transplant Proc. 1998;30:878-880.
25. Bettens F, Kristensen F, Walker C, Schwulera U, Bonnard GD, de Weck AL. Lymphokine regulation of activated (G1) lymphocytes. II. Glucocorticoid and anti-Tac-induced inhibition of human T lymphocyte proliferation. J Immunol. 1984;132:261-265.
26. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004; 11(suppl 1):S45-S55.
27. Oh-i K, Keino H, Goto H, et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Br J Ophthalmol. 2007;91:237-242.
28. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634-641.
29. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000-1006.